The Hindu·3 min read·medium
Dr. Reddy’s to delay semaglutide supplies due to quality issue, shares hit
N
N. Ravi Kumar
✦AI Summary
Dr. Reddy’s Laboratories has halted commercial supplies of its generic semaglutide due to an impurity discovered during production scale-up. The company stated there is no impact on patient safety for products already on the market, but the delay will affect availability in India and Canada.
Dr. Reddy’s Laboratories on Thursday (July 9, 2026) said it has halted commercial supplies of its generic semaglutide after an issue associated with the active pharmaceutical ingredient (API) used in the drug, and fresh despatches were likely to resume only towards late October or early November.
healthbusiness
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in